These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008 [TBL] [Abstract][Full Text] [Related]
5. Engineered PD-L1-Expressing Platelets Reverse New-Onset Type 1 Diabetes. Zhang X; Kang Y; Wang J; Yan J; Chen Q; Cheng H; Huang P; Gu Z Adv Mater; 2020 Jul; 32(26):e1907692. PubMed ID: 32449212 [TBL] [Abstract][Full Text] [Related]
7. Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature. Watanabe T; Firat E; Scholber J; Gaedicke S; Heinrich C; Luo R; Ehrat N; Multhoff G; Schmitt-Graeff A; Grosu AL; Abdollahi A; Hassel JC; von Bubnoff D; Meiss F; Niedermann G Cancer Immunol Immunother; 2020 Sep; 69(9):1823-1832. PubMed ID: 32350591 [TBL] [Abstract][Full Text] [Related]
8. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity. Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075 [TBL] [Abstract][Full Text] [Related]
9. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Tumeh PC; Harview CL; Yearley JH; Shintaku IP; Taylor EJ; Robert L; Chmielowski B; Spasic M; Henry G; Ciobanu V; West AN; Carmona M; Kivork C; Seja E; Cherry G; Gutierrez AJ; Grogan TR; Mateus C; Tomasic G; Glaspy JA; Emerson RO; Robins H; Pierce RH; Elashoff DA; Robert C; Ribas A Nature; 2014 Nov; 515(7528):568-71. PubMed ID: 25428505 [TBL] [Abstract][Full Text] [Related]
10. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells. Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672 [TBL] [Abstract][Full Text] [Related]
14. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy. Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064 [TBL] [Abstract][Full Text] [Related]
15. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment. Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259 [TBL] [Abstract][Full Text] [Related]
16. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma. Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887 [TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes. Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813 [TBL] [Abstract][Full Text] [Related]
18. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845 [TBL] [Abstract][Full Text] [Related]
19. PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy. Zhang X; Wang C; Wang J; Hu Q; Langworthy B; Ye Y; Sun W; Lin J; Wang T; Fine J; Cheng H; Dotti G; Huang P; Gu Z Adv Mater; 2018 May; 30(22):e1707112. PubMed ID: 29656492 [TBL] [Abstract][Full Text] [Related]
20. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. Wang J; Fei K; Jing H; Wu Z; Wu W; Zhou S; Ni H; Chen B; Xiong Y; Liu Y; Peng B; Yu D; Jiang H; Liu J MAbs; 2019; 11(8):1443-1451. PubMed ID: 31402780 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]